Sort by
Refine Your Search
-
Listed
-
Program
-
Employer
-
Field
-
correlations. Candidates should hold a Master in Nanosciences, Biomedical Engineering, Health Sciences and Technology, Biology, Chemistry, or similar, from an institute of higher education that is accepted by
-
, imaging or diagnosis. This PhD project will develop stimuli-responsive nanozyme coatings for personalized medical implants. Nanozymes are nanomaterials capable of mimicking the catalytic activity of natural
-
uncertainty, detect errors, and regulate their behavior accordingly. The PhD project will examine how metacognitive monitoring and regulation develop across different age groups and within individuals over time
-
, and interdependent pathways) using time-resolved and spatially resolved spectroscopy, patterned illumination, and pH/thermal stimuli. Develop and validate logic maps for memory formation, consolidation
-
heat stress and improve thermal safety, comfort, and performance in challenging environments. Your tasks Your task will be Develop, adapt, and validate experimental and computational methods
-
graduate during the starting phase of his/her PhD research project. It is expected that he/she will develop a funding proposal during the first six months for applying to the Swiss National Science
-
intended to contribute to living expenses during the elaboration phase of a dissertation project in literary studies. The aim of the start-up grant is to prepare and submit a competitive application for
-
of their PhD, during which they will develop research proposals for submission to a funding body in order to acquire financial sup-port for the remaining duration of their PhD-projects. The payment of the second
-
. Empa is a research institution of the ETH Domain. At Empa's Laboratory for Biointerfaces and Center for X-ray Analytics , we develop and characterize advanced nanosystems for biomedical applications
-
. This project aims to identify novel tumor-reactive T-cell receptors (TCRs) that can be translated into next-generation adoptive T-cell therapies. The successful candidate will develop patient-derived tumor